# RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers

> **NCT04037358** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 64 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Radium-223
- **RADIATION:** stereotactic ablative radiotherapy (SABR)

## Key facts

- **NCT ID:** NCT04037358
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-09
- **Primary completion:** 2025-07-15
- **Final completion:** 2025-07-15
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04037358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04037358, "RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04037358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*